Kynurenines: From the perspective of major psychiatric disorders

FEBS Journal

Volumn 279, Issue 8, 2012, Pages 1375-1385

  Myint, Aye M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

bipolar; depression; inflammation; kynurenic acid; kynurenine; NMDA; psychiatry; quinolinic acid; schizophrenia; tryptophan

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CLOZAPINE; ESTROGEN; HALOPERIDOL; KYNURENINE; QUINOLINIC ACID; RACLOPRIDE; TRYPTOPHAN;

AMINO ACID BRAIN LEVEL; AMINO ACID METABOLISM; BIPOLAR MANIA; CATABOLISM; CHEMICAL INTERACTION; DEPRESSION; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRYPTOPHAN METABOLISM;

ANIMALS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; KYNURENINE; SCHIZOPHRENIA;

ANIMALIA;

EID: 84859563380     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08551.x     Document Type: Review

References (102)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, et al. (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420, 21-27.
2. Mathers C, &, Loncar D, (2005) Updated Projection of Global Mortality and Burden of Disease, 2002-2030: Data Sources, Methods and Results. WHO, Geneva.
3. Eynard N, Flachaire E, Lestra C, Broyer M, Zaidan R, Claustrat B, &, Quincy C, (1993) Platelet serotonin content and free and total plasma tryptophan in healthy volunteers during 24 hours. Clin Chem 39, 2337-2340.
4. Yuwiler A, Oldendorf WH, Geller E, &, Braun L, (1977) Effect of albumin binding and amino acid competition on tryptophan uptake into brain. J Neurochem 28, 1015-1023.
5. Fernstrom JD, (1977) Effects on the diet on brain neurotransmitters. Metabolism 26, 207-223.
6. Watanabe Y, Fujiwara M, Yoshida R, &, Hayaishi O, (1980) Stereospecificity of hepatic L-tryptophan 2,3-dioxygenase. Biochem J 189, 393-405.
7. Rose DP, &, Adams PW, (1972) Oral contraceptives and tryptophan metabolism: effects of oestrogen in low dose combined with a progestagen and of a low-dose progestagen (megestrol acetate) given alone. J Clin Pathol 25, 252-258.
8. Leklem JE, (1971) Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr 24, 659-672.
9. Hankes LV, Leklem JE, Brown RR, &, Mekel RC, (1971) Tryptophan metabolism in patients with pellagra: problem of vitamin B6 enzyme activity and feedback control of tryptophan pyrrolase enzyme. Am J Clin Nutr 24, 730-739.
10. Ogasawara N, Hagino Y, &, Kotake Y, (1962) Kynurenine-transaminase, kynureninase and the increase of xanthurenic acid excretion. J Biochem 52, 162-166.
11. Bender DA, (1989) Effects of a dietary excess of leucine and of the addition of leucine and 2-oxo-isocaproate on the metabolism of tryptophan and niacin in isolated rat liver cells. Br J Nutr 61, 629-640.
12. Gal EM, &, Sherman AD, (1980) L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5, 223-239.
13. Grant RS, Naif H, Espinosa M, &, Kapoor V, (2000) IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 5, 101-104.
14. Grant RS, &, Kapoor V, (1998) Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 70, 1759-1763.
15. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, &, Markey SP, (1996) Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 320 (Pt 2), 595-597.
16. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, &, Weis S, (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15, 618-629.
17. Guillemin GJ, Smythe G, Takikawa O, &, Brew BJ, (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23.
18. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, &, Brew BJ, (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78, 842-853.
19. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, &, Brew BJ, (2000) Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep 5, 108-111.
20. Quagliariello E, Papa S, Saccone C, &, Alifano A, (1964) Effect of 3-hydroxyanthranilic acid on the mitochondrial respiratory system. Biochem J 91, 137-146.
21. Lardy HA, (1971) The role of tryptophan metabolites in regulating gluconeogenesis. Am J Clin Nutr 24, 764-765.
22. Yuskaitis CJ, &, Jope RS, (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21, 264-273.
23. Heyes MP, Saito K, Major EO, Milstien S, Markey SP, &, Vickers JH, (1993) A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 116, 1425-1450.
24. Mellor AL, &, Munn DH, (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20, 469-473.
25. Moffett JR, Blinder KL, Venkateshan CN, &, Namboodiri MA, (1998) Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res 293, 525-534.
26. Moffett JR, &, Namboodiri MA, (2003) Tryptophan and the immune response. Immunol Cell Biol 81, 247-265.
27. Carlin JM, Borden EC, Sondel PM, &, Byrne GI, (1987) Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 139, 2414-2418.
28. Yasui H, Takai K, Yoshida R, &, Hayaishi O, (1986) Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 83, 6622-6626.
29. Musso T, Gusella GL, Brooks A, Longo DL, &, Varesio L, (1994) Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 83, 1408-1411.
30. Knox WE, (1951) Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system. Br J Exp Pathol 32, 462-469.
31. Salter M, &, Pogson CI, (1985) The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J 229, 499-504.
32. Kotake Y, Ueda T, Mori T, Igaki S, &, Hattori M, (1975) Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid (XA). Acta Vitaminol Enzymol 29, 236-239.
33. Chiarugi A, Calvani M, Meli E, Traggiai E, &, Moroni F, (2001) Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 120, 190-198.
34. Heyes MP, &, Lackner A, (1990) Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. J Neurochem 55, 338-341.
35. Melillo G, Cox GW, Radzioch D, &, Varesio L, (1993) Picolinic acid, a catabolite of L-tryptophan, is a costimulus for the induction of reactive nitrogen intermediate production in murine macrophages. J Immunol 150, 4031-4040.
36. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, &, Ferrara GB, (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196, 459-468.
37. Pertz H, &, Back W, (1988) Synthesis and resolution of chiral ring-opened serotonin analogs of the 5-hydroxykynuramine type. Pharm Acta Helv 63, 128-131.
38. Bender DA, &, McCreanor GM, (1985) Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 13, 441-443.
39. Okuda S, Nishiyama N, Saito H, &, Katsuki H, (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70, 299-307.
40. Schwarcz R, Whetsell WO Jr, &, Mangano RM, (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318.
41. Guillemin GJ, (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279, 1356-1365.
42. Reference withdrawn.
43. Perkins MN, &, Stone TW, (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247, 184-187.
44. Kim JP, &, Choi DW, (1987) Quinolinate neurotoxicity in cortical cell culture. Neuroscience 23, 423-432.
45. Halperin JJ, &, Heyes MP, (1992) Neuroactive kynurenines in Lyme borreliosis. Neurology 42, 43-50.
46. Petzold A, Brassat D, Mas P, Rejdak K, Keir G, Giovannoni G, Thompson EJ, &, Clanet M, (2004) Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 10, 281-283.
47. Rejdak K, Petzold A, Kocki T, Kurzepa J, Grieb P, Turski WA, &, Stelmasiak Z, (2007) Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm 114, 1011-1015.
48. Guillemin GJ, &, Brew BJ, (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7, 199-206.
49. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, &, Sesma MA, (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
50. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, &, Sher E, (2002) 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 43, 374-384.
51. Mannaioni G, Carpenedo R, &, Moroni F, (2003) 5-hydroxyindole causes convulsions and increases transmitter release in the CA1 region of the rat hippocampus. Br J Pharmacol 138, 245-253.
52. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, &, Albuquerque EX, (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases nonalpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21, 7463-7473.
53. Shepard PD, Joy B, Clerkin L, &, Schwarcz R, (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28, 1454-1462.
54. Grilli M, Raiteri L, Patti L, Parodi M, Robino F, Raiteri M, &, Marchi M, (2006) Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br J Pharmacol 149, 724-732.
55. Wu HQ, Rassoulpour A, &, Schwarcz R, (2007) Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm 114, 33-41.
56. Bae SJ, Lee JS, Lee EK, Kim JM, Choi J, Heo HS, Yu BP, &, Chung HY, (2010) The antiapoptotic action of 5-hydroxyindole: protection of mitochondrial integrity. Biol Pharm Bull 33, 550-555.
57. Linetsky M, James HL, &, Ortwerth BJ, (1999) Spontaneous generation of superoxide anion by human lens proteins and by calf lens proteins ascorbylated in vitro. Exp Eye Res 69, 239-248.
58. Maes M, (1994) Cytokines in major depression. Biol Psychiatry 36, 498-499.
59. Myint AM, Leonard BE, Steinbusch HW, &, Kim YK, (2005) Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88, 167-173.
60. Schiepers OJ, Wichers MC, &, Maes M, (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29, 201-217.
61. Kaestner F, Hettich M, Peters M, Sibrowski W, Hetzel G, Ponath G, Arolt V, Cassens U, &, Rothermundt M, (2005) Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 87, 305-311.
62. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, &, O'Brien JT, (2005) Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162, 175-177.
63. Mikova O, Yakimova R, Bosmans E, Kenis G, &, Maes M, (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11, 203-208.
64. Connor TJ, &, Leonard BE, (1998) Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62, 583-606.
65. Anisman H, Ravindran AV, Griffiths J, &, Merali Z, (1999) Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4, 182-188.
66. Lanquillon S, Krieg JC, Bening-Abu-Shach U, &, Vedder H, (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379.
67. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, &, Licinio J, (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 7, 1107-1114.
68. Myint AM, &, Kim YK, (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61, 519-525.
69. Appel E, Kolman O, Kazimirsky G, Blumberg PM, &, Brodie C, (1997) Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. NeuroReport 8, 3309-3312.
70. Lavoie J, Giguere JF, Layrargues GP, &, Butterworth RF, (1987) Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab Brain Dis 2, 283-290.
71. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, &, Leonard B, (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98, 143-151.
72. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249-1273.
73. Steiner J, Gos T, Bogerts B, Mawrin C, Guillemin GJ, zu Schwabedissen LM, Fenker DB, Bernstein H-G, Keilhoff G, Ankowski JZ, et al. (2011) Severe depression is associated with increased quinolinic acid immunoreactivity in the dorsal and ventral anterior cingulum: further evidence for an immune modulation of glutamatergic neurotransmission. J Neuroinflammation 8, 9.
74. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, &, Stockmeier CA, (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45, 1085-1098.
75. Gabbay V, Liebes L, Katz Y, Liu S, Mendoza S, Babb JS, Klein RG, &, Gonen O, (2010) The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 34, 37-44.
76. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, &, Maes M, (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10, 538-544.
77. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, &, Miller AH, (2000) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15, 393-403.
78. Miller CL, Llenos IC, Dulay JR, &, Weis S, (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074, 25-37.
79. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, &, Leonard BE, (2007) Tryptophan breakdown pathway in bipolar mania. J Affect Disord 102, 65-72.
80. Kim YK, Jung HG, Myint AM, Kim H, &, Park SH, (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104, 91-95.
81. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, Kelley KW, &, Dantzer R, (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14, 511-522.
82. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, &, Kelley KW, (2009) Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 182, 3202-3212.
83. O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, &, Dantzer R, (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29, 4200-4209.
84. Mason M, &, Manning B, (1971) Effects of steroid conjugates on availability of pyridoxal phosphate for kynureninase and kynurenine aminotransferase activity. Am J Clin Nutr 24, 786-791.
85. Xiong H, Zhou C, &, Qi G, (2010) Proportional changes of CD4+CD25+Foxp3+ regulatory T cells in maternal peripheral blood during pregnancy and labor at term and preterm. Clin Invest Med 33, E422.
86. Rapaport MH, McAllister CG, Pickar D, Nelson DL, &, Paul SM, (1989) Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch Gen Psychiatry 46, 291-292.
87. Moises HW, Schindler L, Leroux M, &, Kirchner H, (1985) Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients. Acta Psychiatr Scand 72, 45-50.
88. Schwarz MJ, Muller N, Riedel M, &, Ackenheil M, (2001) The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56, 483-486.
89. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A, &, Clerici M, (2001) Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 47, 293-298.
90. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, &, Leonard BE, (2004) Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28, 1129-1134.
91. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, &, Kouassi E, (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63, 801-808.
92. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, &, Roberts RC, (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50, 521-530.
93. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, &, Engberg G, (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313, 96-98.
94. Erhardt S, Schwieler L, &, Engberg G, (2003) Kynurenic acid and schizophrenia. Adv Exp Med Biol 527, 155-165.
95. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, &, Schwarcz R, (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 113, 1355-1365.
96. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, Cohen G, &, O'Leary DS, (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49, 943-958.
97. Takahashi T, Wood SJ, Soulsby B, McGorry PD, Tanino R, Suzuki M, Velakoulis D, &, Pantelis C, (2009) Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res 108, 49-56.
98. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, &, Kaddurah-Daouk R, (2009) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 15, 938-953.
99. Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, &, Yao JK, (2011) 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 14, 1-12.
100. Erhardt S, Olsson SK, &, Engberg G, (2009) Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 23, 91-101.
101. Myint AM, Schwarz M, Verkerk R, Scharpe S, Steinbusch HWM, Leonard BE, &, Kim YK, (2011) Imbalance of kynurenine metabolites in drug naive schizophrenia. Brain Behav Immun 25, 6.
102. Stone TW, Forrest CM, &, Darlington LG, (2012) Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 279, 1386-1397.